Is Broadcom Stock Overvalued?
The semiconductor company Broadcom Inc. (NASDAQ:AVGO) is having a stellar…
Sell
39
TAK Quote, Financials, Valuation and Earnings
Last price:
$12.96
Seasonality move
:
-0.07%
Day range:
$12.95 - $13.13
52-week range:
$12.58 - $15.08
Dividend yield:
4.78%
P/E ratio:
21.43x
P/S ratio:
1.37x
P/B ratio:
0.85x
Volume:
2.3M
Avg. volume:
1.7M
1-year change:
-12.97%
Market cap:
$41.1B
Revenue:
$29.5B
EPS (TTM):
$0.60
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TAK
Takeda Pharmaceutical
|
$7.5B | -- | 0.1% | -- | $15.66 |
|
AMGXF
AnGes
|
-- | -- | -- | -- | -- |
|
HCM
HUTCHMED (China)
|
-- | -- | -- | -- | $27.13 |
|
HLOSF
Healios KK
|
-- | -- | -- | -- | -- |
|
PPTDF
PeptiDream
|
-- | -- | -- | -- | -- |
|
SOLTF
Nxera Pharma
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TAK
Takeda Pharmaceutical
|
$12.95 | $15.66 | $41.1B | 21.43x | $0.33 | 4.78% | 1.37x |
|
AMGXF
AnGes
|
$0.36 | -- | $86.6M | -- | $0.00 | 0% | 22.98x |
|
HCM
HUTCHMED (China)
|
$15.03 | $27.13 | $2.6B | 34.11x | $0.00 | 0% | 6.24x |
|
HLOSF
Healios KK
|
$0.96 | -- | $86.5M | -- | $0.00 | 0% | 22.75x |
|
PPTDF
PeptiDream
|
$17.85 | -- | $2.3B | 21.21x | $0.00 | 0% | 7.43x |
|
SOLTF
Nxera Pharma
|
$6.52 | -- | $586.2M | -- | $0.00 | 0% | 2.95x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TAK
Takeda Pharmaceutical
|
42.19% | 0.367 | 78.44% | 0.68x |
|
AMGXF
AnGes
|
-- | 2.572 | -- | 1.10x |
|
HCM
HUTCHMED (China)
|
9.99% | 0.683 | 2.79% | 2.39x |
|
HLOSF
Healios KK
|
65.07% | -1.151 | 34.39% | 1.33x |
|
PPTDF
PeptiDream
|
25.75% | -2.102 | 6.45% | 3.28x |
|
SOLTF
Nxera Pharma
|
48.92% | 2.557 | 55.24% | 3.73x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TAK
Takeda Pharmaceutical
|
$5.3B | $1.8B | 2.37% | 4.01% | 15.97% | $1.3B |
|
AMGXF
AnGes
|
$259.5K | -$13M | -37.32% | -22.74% | -1559.14% | -- |
|
HCM
HUTCHMED (China)
|
-- | -- | -5.04% | -5.49% | -- | -- |
|
HLOSF
Healios KK
|
$2.8M | -$1.8M | -55.94% | -137.21% | -24.5% | -$4.8M |
|
PPTDF
PeptiDream
|
$17.4M | -$854.5K | 24.02% | 34.66% | -1.5% | $173.8M |
|
SOLTF
Nxera Pharma
|
$48.9M | $5.4M | -2.75% | -5.58% | 11.44% | $10.3M |
Takeda Pharmaceutical vs. Competitors
-
Which has Higher Returns TAK or AMGXF?
AnGes has a net margin of 7.83% compared to Takeda Pharmaceutical's net margin of -2947.39%. Takeda Pharmaceutical's return on equity of 4.01% beat AnGes's return on equity of -22.74%.
Company Gross Margin Earnings Per Share Invested Capital TAKTakeda Pharmaceutical66.47% $0.19 $83.8B AMGXFAnGes31.07% -$0.11 $158.3M -
What do Analysts Say About TAK or AMGXF?
Takeda Pharmaceutical has a consensus price target of $15.66, signalling upside risk potential of 20.94%. On the other hand AnGes has an analysts' consensus of -- which suggests that it could fall by --. Given that Takeda Pharmaceutical has higher upside potential than AnGes, analysts believe Takeda Pharmaceutical is more attractive than AnGes.
Company Buy Ratings Hold Ratings Sell Ratings TAKTakeda Pharmaceutical3 1 0 AMGXFAnGes0 0 0 -
Is TAK or AMGXF More Risky?
Takeda Pharmaceutical has a beta of 0.504, which suggesting that the stock is 49.642% less volatile than S&P 500. In comparison AnGes has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock TAK or AMGXF?
Takeda Pharmaceutical has a quarterly dividend of $0.33 per share corresponding to a yield of 4.78%. AnGes offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Takeda Pharmaceutical pays 199.34% of its earnings as a dividend. AnGes pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TAK or AMGXF?
Takeda Pharmaceutical quarterly revenues are $7.9B, which are larger than AnGes quarterly revenues of $835.2K. Takeda Pharmaceutical's net income of $619.7M is higher than AnGes's net income of -$24.6M. Notably, Takeda Pharmaceutical's price-to-earnings ratio is 21.43x while AnGes's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical is 1.37x versus 22.98x for AnGes. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TAKTakeda Pharmaceutical1.37x 21.43x $7.9B $619.7M AMGXFAnGes22.98x -- $835.2K -$24.6M
-
Which has Higher Returns TAK or HCM?
HUTCHMED (China) has a net margin of 7.83% compared to Takeda Pharmaceutical's net margin of --. Takeda Pharmaceutical's return on equity of 4.01% beat HUTCHMED (China)'s return on equity of -5.49%.
Company Gross Margin Earnings Per Share Invested Capital TAKTakeda Pharmaceutical66.47% $0.19 $83.8B HCMHUTCHMED (China)-- -- $834.1M -
What do Analysts Say About TAK or HCM?
Takeda Pharmaceutical has a consensus price target of $15.66, signalling upside risk potential of 20.94%. On the other hand HUTCHMED (China) has an analysts' consensus of $27.13 which suggests that it could grow by 80.49%. Given that HUTCHMED (China) has higher upside potential than Takeda Pharmaceutical, analysts believe HUTCHMED (China) is more attractive than Takeda Pharmaceutical.
Company Buy Ratings Hold Ratings Sell Ratings TAKTakeda Pharmaceutical3 1 0 HCMHUTCHMED (China)10 2 0 -
Is TAK or HCM More Risky?
Takeda Pharmaceutical has a beta of 0.504, which suggesting that the stock is 49.642% less volatile than S&P 500. In comparison HUTCHMED (China) has a beta of 0.808, suggesting its less volatile than the S&P 500 by 19.209%.
-
Which is a Better Dividend Stock TAK or HCM?
Takeda Pharmaceutical has a quarterly dividend of $0.33 per share corresponding to a yield of 4.78%. HUTCHMED (China) offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Takeda Pharmaceutical pays 199.34% of its earnings as a dividend. HUTCHMED (China) pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TAK or HCM?
Takeda Pharmaceutical quarterly revenues are $7.9B, which are larger than HUTCHMED (China) quarterly revenues of --. Takeda Pharmaceutical's net income of $619.7M is higher than HUTCHMED (China)'s net income of --. Notably, Takeda Pharmaceutical's price-to-earnings ratio is 21.43x while HUTCHMED (China)'s PE ratio is 34.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical is 1.37x versus 6.24x for HUTCHMED (China). Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TAKTakeda Pharmaceutical1.37x 21.43x $7.9B $619.7M HCMHUTCHMED (China)6.24x 34.11x -- --
-
Which has Higher Returns TAK or HLOSF?
Healios KK has a net margin of 7.83% compared to Takeda Pharmaceutical's net margin of -107.23%. Takeda Pharmaceutical's return on equity of 4.01% beat Healios KK's return on equity of -137.21%.
Company Gross Margin Earnings Per Share Invested Capital TAKTakeda Pharmaceutical66.47% $0.19 $83.8B HLOSFHealios KK86.35% -$0.04 $57.8M -
What do Analysts Say About TAK or HLOSF?
Takeda Pharmaceutical has a consensus price target of $15.66, signalling upside risk potential of 20.94%. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that Takeda Pharmaceutical has higher upside potential than Healios KK, analysts believe Takeda Pharmaceutical is more attractive than Healios KK.
Company Buy Ratings Hold Ratings Sell Ratings TAKTakeda Pharmaceutical3 1 0 HLOSFHealios KK0 0 0 -
Is TAK or HLOSF More Risky?
Takeda Pharmaceutical has a beta of 0.504, which suggesting that the stock is 49.642% less volatile than S&P 500. In comparison Healios KK has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock TAK or HLOSF?
Takeda Pharmaceutical has a quarterly dividend of $0.33 per share corresponding to a yield of 4.78%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Takeda Pharmaceutical pays 199.34% of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TAK or HLOSF?
Takeda Pharmaceutical quarterly revenues are $7.9B, which are larger than Healios KK quarterly revenues of $3.2M. Takeda Pharmaceutical's net income of $619.7M is higher than Healios KK's net income of -$3.4M. Notably, Takeda Pharmaceutical's price-to-earnings ratio is 21.43x while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical is 1.37x versus 22.75x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TAKTakeda Pharmaceutical1.37x 21.43x $7.9B $619.7M HLOSFHealios KK22.75x -- $3.2M -$3.4M
-
Which has Higher Returns TAK or PPTDF?
PeptiDream has a net margin of 7.83% compared to Takeda Pharmaceutical's net margin of -5.57%. Takeda Pharmaceutical's return on equity of 4.01% beat PeptiDream's return on equity of 34.66%.
Company Gross Margin Earnings Per Share Invested Capital TAKTakeda Pharmaceutical66.47% $0.19 $83.8B PPTDFPeptiDream47.13% -$0.02 $551.4M -
What do Analysts Say About TAK or PPTDF?
Takeda Pharmaceutical has a consensus price target of $15.66, signalling upside risk potential of 20.94%. On the other hand PeptiDream has an analysts' consensus of -- which suggests that it could fall by --. Given that Takeda Pharmaceutical has higher upside potential than PeptiDream, analysts believe Takeda Pharmaceutical is more attractive than PeptiDream.
Company Buy Ratings Hold Ratings Sell Ratings TAKTakeda Pharmaceutical3 1 0 PPTDFPeptiDream0 0 0 -
Is TAK or PPTDF More Risky?
Takeda Pharmaceutical has a beta of 0.504, which suggesting that the stock is 49.642% less volatile than S&P 500. In comparison PeptiDream has a beta of 0.804, suggesting its less volatile than the S&P 500 by 19.554%.
-
Which is a Better Dividend Stock TAK or PPTDF?
Takeda Pharmaceutical has a quarterly dividend of $0.33 per share corresponding to a yield of 4.78%. PeptiDream offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Takeda Pharmaceutical pays 199.34% of its earnings as a dividend. PeptiDream pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TAK or PPTDF?
Takeda Pharmaceutical quarterly revenues are $7.9B, which are larger than PeptiDream quarterly revenues of $36.8M. Takeda Pharmaceutical's net income of $619.7M is higher than PeptiDream's net income of -$2.1M. Notably, Takeda Pharmaceutical's price-to-earnings ratio is 21.43x while PeptiDream's PE ratio is 21.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical is 1.37x versus 7.43x for PeptiDream. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TAKTakeda Pharmaceutical1.37x 21.43x $7.9B $619.7M PPTDFPeptiDream7.43x 21.21x $36.8M -$2.1M
-
Which has Higher Returns TAK or SOLTF?
Nxera Pharma has a net margin of 7.83% compared to Takeda Pharmaceutical's net margin of 12.96%. Takeda Pharmaceutical's return on equity of 4.01% beat Nxera Pharma's return on equity of -5.58%.
Company Gross Margin Earnings Per Share Invested Capital TAKTakeda Pharmaceutical66.47% $0.19 $83.8B SOLTFNxera Pharma78.44% $0.09 $928.9M -
What do Analysts Say About TAK or SOLTF?
Takeda Pharmaceutical has a consensus price target of $15.66, signalling upside risk potential of 20.94%. On the other hand Nxera Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Takeda Pharmaceutical has higher upside potential than Nxera Pharma, analysts believe Takeda Pharmaceutical is more attractive than Nxera Pharma.
Company Buy Ratings Hold Ratings Sell Ratings TAKTakeda Pharmaceutical3 1 0 SOLTFNxera Pharma0 0 0 -
Is TAK or SOLTF More Risky?
Takeda Pharmaceutical has a beta of 0.504, which suggesting that the stock is 49.642% less volatile than S&P 500. In comparison Nxera Pharma has a beta of 0.401, suggesting its less volatile than the S&P 500 by 59.86%.
-
Which is a Better Dividend Stock TAK or SOLTF?
Takeda Pharmaceutical has a quarterly dividend of $0.33 per share corresponding to a yield of 4.78%. Nxera Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Takeda Pharmaceutical pays 199.34% of its earnings as a dividend. Nxera Pharma pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TAK or SOLTF?
Takeda Pharmaceutical quarterly revenues are $7.9B, which are larger than Nxera Pharma quarterly revenues of $62.4M. Takeda Pharmaceutical's net income of $619.7M is higher than Nxera Pharma's net income of $8.1M. Notably, Takeda Pharmaceutical's price-to-earnings ratio is 21.43x while Nxera Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical is 1.37x versus 2.95x for Nxera Pharma. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TAKTakeda Pharmaceutical1.37x 21.43x $7.9B $619.7M SOLTFNxera Pharma2.95x -- $62.4M $8.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
4 Top Dividend Stocks to Buy Now
If you’re looking for steady income, dividend stocks are a…
Will Uber Stock Recover?
Shares of Uber Technologies (NYSE:UBER) have had a rough few…
Stock Ideas
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 39x
Sell
47
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 114x
Sell
39
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Buy
87
CEG alert for Jan 11
Constellation Energy [CEG] is up 25.15% over the past day.
Sell
1
MCY alert for Jan 11
Mercury General [MCY] is down 19.87% over the past day.
Buy
84
ATZAF alert for Jan 11
Aritzia [ATZAF] is up 17.63% over the past day.
